Pleomorphic Xanthoastrocytoma with Anaplastic Features: Retrospective Case Series

Martin J. Rutkowski, Taemin Oh, Gulen G. Niflioglu, Michael Safaee, Tarik Tihan, Andrew T. Parsa

Research output: Contribution to journalArticle

Abstract

Objective Pleomorphic xanthoastrocytoma (PXA) is a unique meningocerebral glioma with a relatively favorable prognosis. PXA also possesses a variant with anaplastic features (aPXA), which is associated with poor outcomes. To date, few studies have examined the clinicopathologic importance of these anaplastic features. Methods From 1999–2012, 8 patients with aPXA were treated at the University of California, San Francisco, California, United States. Cases were reconfirmed by neuropathology, and clinical information regarding patient demographics, tumor characteristics, and treatment outcomes was assembled. Tumors were classified as aPXA according to the World Health Organization diagnostic criteria established in 2007. Results There were 5 female and 3 male patients in our cohort, ranging in age from 4–74 years at initial diagnosis. Seizure was the most common presenting symptom (50%), and the majority of tumors arose in the frontal or temporal lobes (88%). Six patients received subtotal resection (STR), and all suffered from progression despite adjuvant radiotherapy and chemotherapy. Median time to progression was 20 months, with a 1-year progression-free survival rate of 57%. Three aPXA patients expired with a median survival of 87 months. Four patients developed disseminated disease. Three of 8 (38%) showed BRAFv600 mutation. Conclusion aPXA is associated with poorer clinical outcomes compared with PXA. Gross total resection should be the goal of initial treatment. It remains unclear whether adjuvant radiation and chemotherapy are able to prevent progression or dissemination. Long-term monitoring of all patients is a critical step in management due to the potential for tumors to transform into higher-grade lesions.

Original languageEnglish (US)
Pages (from-to)368-374
Number of pages7
JournalWorld Neurosurgery
Volume95
DOIs
StatePublished - Nov 1 2016

Fingerprint

Adjuvant Chemotherapy
Neoplasms
Adjuvant Radiotherapy
San Francisco
Physiologic Monitoring
Frontal Lobe
Temporal Lobe
Glioma
Disease-Free Survival
Seizures
Survival Rate
Demography
Radiation
Mutation
Survival
Therapeutics
Neuropathology

Keywords

  • Anaplastic
  • Astrocytoma
  • Glioblastoma
  • Glioma
  • Outcomes
  • Pleomorphic
  • Surgery
  • Treatment
  • Xanthoastrocytoma

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Rutkowski, M. J., Oh, T., Niflioglu, G. G., Safaee, M., Tihan, T., & Parsa, A. T. (2016). Pleomorphic Xanthoastrocytoma with Anaplastic Features: Retrospective Case Series. World Neurosurgery, 95, 368-374. https://doi.org/10.1016/j.wneu.2016.07.068

Pleomorphic Xanthoastrocytoma with Anaplastic Features : Retrospective Case Series. / Rutkowski, Martin J.; Oh, Taemin; Niflioglu, Gulen G.; Safaee, Michael; Tihan, Tarik; Parsa, Andrew T.

In: World Neurosurgery, Vol. 95, 01.11.2016, p. 368-374.

Research output: Contribution to journalArticle

Rutkowski, MJ, Oh, T, Niflioglu, GG, Safaee, M, Tihan, T & Parsa, AT 2016, 'Pleomorphic Xanthoastrocytoma with Anaplastic Features: Retrospective Case Series', World Neurosurgery, vol. 95, pp. 368-374. https://doi.org/10.1016/j.wneu.2016.07.068
Rutkowski, Martin J. ; Oh, Taemin ; Niflioglu, Gulen G. ; Safaee, Michael ; Tihan, Tarik ; Parsa, Andrew T. / Pleomorphic Xanthoastrocytoma with Anaplastic Features : Retrospective Case Series. In: World Neurosurgery. 2016 ; Vol. 95. pp. 368-374.
@article{6ae32d205202433b8322687850431a8e,
title = "Pleomorphic Xanthoastrocytoma with Anaplastic Features: Retrospective Case Series",
abstract = "Objective Pleomorphic xanthoastrocytoma (PXA) is a unique meningocerebral glioma with a relatively favorable prognosis. PXA also possesses a variant with anaplastic features (aPXA), which is associated with poor outcomes. To date, few studies have examined the clinicopathologic importance of these anaplastic features. Methods From 1999–2012, 8 patients with aPXA were treated at the University of California, San Francisco, California, United States. Cases were reconfirmed by neuropathology, and clinical information regarding patient demographics, tumor characteristics, and treatment outcomes was assembled. Tumors were classified as aPXA according to the World Health Organization diagnostic criteria established in 2007. Results There were 5 female and 3 male patients in our cohort, ranging in age from 4–74 years at initial diagnosis. Seizure was the most common presenting symptom (50{\%}), and the majority of tumors arose in the frontal or temporal lobes (88{\%}). Six patients received subtotal resection (STR), and all suffered from progression despite adjuvant radiotherapy and chemotherapy. Median time to progression was 20 months, with a 1-year progression-free survival rate of 57{\%}. Three aPXA patients expired with a median survival of 87 months. Four patients developed disseminated disease. Three of 8 (38{\%}) showed BRAFv600 mutation. Conclusion aPXA is associated with poorer clinical outcomes compared with PXA. Gross total resection should be the goal of initial treatment. It remains unclear whether adjuvant radiation and chemotherapy are able to prevent progression or dissemination. Long-term monitoring of all patients is a critical step in management due to the potential for tumors to transform into higher-grade lesions.",
keywords = "Anaplastic, Astrocytoma, Glioblastoma, Glioma, Outcomes, Pleomorphic, Surgery, Treatment, Xanthoastrocytoma",
author = "Rutkowski, {Martin J.} and Taemin Oh and Niflioglu, {Gulen G.} and Michael Safaee and Tarik Tihan and Parsa, {Andrew T.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.wneu.2016.07.068",
language = "English (US)",
volume = "95",
pages = "368--374",
journal = "World Neurosurgery",
issn = "1878-8750",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Pleomorphic Xanthoastrocytoma with Anaplastic Features

T2 - Retrospective Case Series

AU - Rutkowski, Martin J.

AU - Oh, Taemin

AU - Niflioglu, Gulen G.

AU - Safaee, Michael

AU - Tihan, Tarik

AU - Parsa, Andrew T.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Objective Pleomorphic xanthoastrocytoma (PXA) is a unique meningocerebral glioma with a relatively favorable prognosis. PXA also possesses a variant with anaplastic features (aPXA), which is associated with poor outcomes. To date, few studies have examined the clinicopathologic importance of these anaplastic features. Methods From 1999–2012, 8 patients with aPXA were treated at the University of California, San Francisco, California, United States. Cases were reconfirmed by neuropathology, and clinical information regarding patient demographics, tumor characteristics, and treatment outcomes was assembled. Tumors were classified as aPXA according to the World Health Organization diagnostic criteria established in 2007. Results There were 5 female and 3 male patients in our cohort, ranging in age from 4–74 years at initial diagnosis. Seizure was the most common presenting symptom (50%), and the majority of tumors arose in the frontal or temporal lobes (88%). Six patients received subtotal resection (STR), and all suffered from progression despite adjuvant radiotherapy and chemotherapy. Median time to progression was 20 months, with a 1-year progression-free survival rate of 57%. Three aPXA patients expired with a median survival of 87 months. Four patients developed disseminated disease. Three of 8 (38%) showed BRAFv600 mutation. Conclusion aPXA is associated with poorer clinical outcomes compared with PXA. Gross total resection should be the goal of initial treatment. It remains unclear whether adjuvant radiation and chemotherapy are able to prevent progression or dissemination. Long-term monitoring of all patients is a critical step in management due to the potential for tumors to transform into higher-grade lesions.

AB - Objective Pleomorphic xanthoastrocytoma (PXA) is a unique meningocerebral glioma with a relatively favorable prognosis. PXA also possesses a variant with anaplastic features (aPXA), which is associated with poor outcomes. To date, few studies have examined the clinicopathologic importance of these anaplastic features. Methods From 1999–2012, 8 patients with aPXA were treated at the University of California, San Francisco, California, United States. Cases were reconfirmed by neuropathology, and clinical information regarding patient demographics, tumor characteristics, and treatment outcomes was assembled. Tumors were classified as aPXA according to the World Health Organization diagnostic criteria established in 2007. Results There were 5 female and 3 male patients in our cohort, ranging in age from 4–74 years at initial diagnosis. Seizure was the most common presenting symptom (50%), and the majority of tumors arose in the frontal or temporal lobes (88%). Six patients received subtotal resection (STR), and all suffered from progression despite adjuvant radiotherapy and chemotherapy. Median time to progression was 20 months, with a 1-year progression-free survival rate of 57%. Three aPXA patients expired with a median survival of 87 months. Four patients developed disseminated disease. Three of 8 (38%) showed BRAFv600 mutation. Conclusion aPXA is associated with poorer clinical outcomes compared with PXA. Gross total resection should be the goal of initial treatment. It remains unclear whether adjuvant radiation and chemotherapy are able to prevent progression or dissemination. Long-term monitoring of all patients is a critical step in management due to the potential for tumors to transform into higher-grade lesions.

KW - Anaplastic

KW - Astrocytoma

KW - Glioblastoma

KW - Glioma

KW - Outcomes

KW - Pleomorphic

KW - Surgery

KW - Treatment

KW - Xanthoastrocytoma

UR - http://www.scopus.com/inward/record.url?scp=84987933179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987933179&partnerID=8YFLogxK

U2 - 10.1016/j.wneu.2016.07.068

DO - 10.1016/j.wneu.2016.07.068

M3 - Article

C2 - 27476694

AN - SCOPUS:84987933179

VL - 95

SP - 368

EP - 374

JO - World Neurosurgery

JF - World Neurosurgery

SN - 1878-8750

ER -